Match prostate cancer screening to who can actually benefit

Design

Retrospective national cohort comparison, linked VA–Medicare data (observational)

Population

1.41 million male veterans aged ≥65, 2004–2023

Primary outcome

PSA testing and biopsy rates per 1000 person-years by age and life expectancy

Effect

Age ≥80 testing IRR 0.70, biopsy 0.67; <5-year life expectancy 0.84; age 65–69 testing 1.10

A comparison of 1.41 million older male veterans dually enrolled in VA and fee-for-service Medicare examined where PSA testing and biopsy were concentrated. The principle it tests is settled: PSA screening in men with limited life expectancy is low-value, because the lead time is longer than the time they have.

VA primary care aligned testing more closely with benefit. Among men aged 80 or over it tested less (incidence rate ratio 0.70) and biopsied less (0.67) than Medicare, and it tested less in men with under five years' predicted life expectancy (0.84) — while testing slightly more in men aged 65 to 69 (1.10), where benefit is plausible. The difference is in matching intensity to the patient, not in testing less across the board.

The practice point travels anywhere PSA is ordered opportunistically, India included: before sending a PSA, ask whether this man is likely to live long enough to benefit, and whether he has been offered the choice.

• Before ordering a PSA, estimate whether the man is likely to live long enough to benefit.
• Avoid routine PSA testing in men over 80 or with under five years' life expectancy.
• Reserve screening for men whose age and health make benefit plausible, after a shared decision.
• Lower testing here meant fewer biopsies in the men least likely to gain, not blanket rationing.

Why it matters

It shows screening restraint can be targeted rather than blanket, concentrating testing on the men who stand to gain.

Don't overread it

This compares testing patterns between health systems, not patient outcomes — it shows who was screened, not that less screening changed survival.

The statistics, in plain English

The incidence rate ratios describe how often testing happened, not whether outcomes improved; the value of the study is in showing restraint was targeted by age and life expectancy, which is what low-value-care guidance asks for.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.